- Home
- KC vs RCUS Comparison
KC vs RCUS Comparison
Compare KC & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KC | RCUS |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.2B |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | KC | RCUS |
|---|---|---|
| Price | $9.42 | $24.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 10 |
| Target Price | $18.00 | ★ $31.90 |
| AVG Volume (30 Days) | 1.1M | ★ 1.6M |
| Earning Date | 05-27-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $247,000,000.00 |
| Revenue This Year | $30.93 | N/A |
| Revenue Next Year | $20.45 | $45.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.35 | $12.89 |
| 52 Week High | $18.52 | $31.74 |
Technical Indicators
Market Signals| Indicator | KC | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 39.51 | 38.72 |
| Support Level | $9.29 | $22.92 |
| Resistance Level | $11.06 | $26.43 |
| Average True Range (ATR) | 0.25 | 1.31 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 10.81 | 27.71 |
Price Performance
Historical ComparisonAbout KC Kingsoft Cloud Holdings Limited
Kingsoft Cloud Holdings Ltd is an independent cloud service provider in China. It provides integrated cloud-based services including cloud computing, storage, and delivery. Its products and services are Security, Database, Data Analysis, Networking, and others. Its solutions are medical, government affairs, finance, media, education, gaming, Vehicle solutions, and others.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.